Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
| Revenue (TTM) | $179.09M |
| Gross Profit (TTM) | $77.04M |
| EBITDA | $11.88M |
| Operating Margin | 15.40% |
| Return on Equity | 7.05% |
| Return on Assets | -0.10% |
| Revenue/Share (TTM) | $0.47 |
| Book Value | $2.88 |
| Price-to-Book | 1.08 |
| Price-to-Sales (TTM) | 6.48 |
| EV/Revenue | 1.996 |
| EV/EBITDA | 39.66 |
| Quarterly Earnings Growth (YoY) | 126.80% |
| Quarterly Revenue Growth (YoY) | 58.40% |
| Shares Outstanding | $368.41M |
| Float | $186.99M |
| % Insiders | 48.85% |
| % Institutions | 15.48% |
Volatility is currently expanding
Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cronos delivered a Q2 2026 earnings report that met bullish investor expectations. Strong quarterly performance reinforces the investment thesis for CRON's growth trajectory. Management execution and financial results support a positive outlook for CRON.
Cronos Group Inc. is rapidly expanding internationally, leveraging European legalization momentum and the CanAdelaar acquisition to become a major European cannabis player. Q2 results showed 58% YoY revenue growth to $53M, with margins benefiting from favorable sales mix and stable operating expenses. CRON maintains a robust balance sheet with nearly $800M in cash and short-term investments versus $56M in current liabilities, supporting buybacks and future M&A.
Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript
Cronos Group NASDAQ: CRON reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany.
Cronos Group (CRON) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis Delivered record net revenue in Canada, with Spinach® maintaining #1 market share in vapes and edibles1 Tenth consecutive quarter of record net revenue in Israel, where PEACE NATURALS® continues to be the #1 cannabis brand2 Generated record net revenue outside Canada and Israel, led by strong demand for PEACE NATURALS® in Germany Repurchased 12.3 million shares in the first half of 2026 TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2026 second quarter business results. “Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count.
There is a great divide between big cannabis companies like Trulieve cannabis corp. Tilray Holdings Inc., and it's not with each other. The separation is what smaller mom-and-pop cannabis farmers are going to do as the big fish takes over the market. As legal cannabis grows, so does the competition, and this leads to a bittersweet result. For investors and those who hold shares of said big company, it is usually the one that wins in the long run. Marijuana stock investors are focused on companies that show profitability and a path towards change and innovation.
Flavors with rare cannabinoid formulations from SOURZ by Spinach®, along with a new limited-time offer flavor, are now available in the popular multipack format Flavors with rare cannabinoid formulations from SOURZ by Spinach®, along with a new limited-time offer flavor, are now available in the popular multipack format
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRON and any ticker you trade — then tracks every position and per-strategy win rate.
